Cognitive Behavior Therapy for Anxiety-related Asthma in Adults.

Not Applicable

Completed

• Conditions: Asthma

• Registration Number: NCT03158194
• Lead Sponsor: Karolinska Institutet

Brief Summary

This is a study to develop a protocol on Cognitive behavior therapy (CBT) for asthma-related anxiety that in a consecutive study can be translated to internet-delivered CBT.

Detailed Description

Asthma is one of the most common chronic diseases around the world, with a high prevalence of anxiety disorders. Cognitive behaviour therapy (CBT) has been shown to increase psychological well-being for anxiety-related asthma. Our primary aim is to develop a standardized CBT protocol for asthma-related anxiety that can be transferred to internet-delivered CBT. Ten participants will be included in a single-subject multiple baseline design. They will all receive 10-12 sessions of CBT.

Study Timeline

• Study First Submitted: 2017-05-16
• Study First Submitted QC: 2017-05-16
• Study First Posted: 2017-05-18
• Study Start: 2017-08-16
• Status Verified: 2018-03
• Primary Completion: 2018-03-07
• Study Completion: 2018-03-07
• Last Update Submitted: 2018-03-07
• Last Update Posted: 2018-03-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• asthma diagnosed by a physician
• anxiety or stress related to asthma

Exclusion Criteria

• severe psychiatric disorder (e.g. psychotic disorder, addiction disorder, suicidal ideation).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Penn State Worry Questionnaire	Baseline to 12 weeks	Change in subjective worry measured with a self-rating scale weekly during 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect.

Secondary Outcome Measures

Name	Time	Method
Anxiety Sensitivity Index-3	Baseline to 12 weeks	Change in anxiety sensitivity measured with a self-rating scale weekly during 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect.
Short Health Anxiety Inventory (SHAI)	Baseline to 12 weeks	Change in health anxiety measured with a self-rating scale weekly during 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect.
Asthma Quality of Life Questionnaire	Baseline to 12 weeks	Change in asthma-related quality of life measured with a self-rating scale at pretreatment and at 10 to 12 weeks post treatment for analysis of effect.
Asthma control test	Baseline to 12 weeks	Change in asthma control measured with a self-rating scale daily during weekly 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect.
Catastrophizing about asthma Scale	Baseline to 12 weeks	Change in catastrophizing cognitions about asthma measured with a self-rating scale weekly during 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect.
Perceived Stress Scale	Baseline to 12 weeks	Change in perceived stress measured with a self-rating scale weekly 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect.
Patient Health Questionnaire	Baseline to 12 weeks	Change in depression measured with a self-rating scale at baseline and at 10 to 12 weeks post treatment for analysis of effect.

Trial Locations

Locations (1)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet; 🇸🇪 Stockholm, Sweden